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ABSTRACT 
Insufficient activity of the bone-forming osteoblasts leads to low bone mass and predisposes to 
fragility fractures. The functional capacity of mesenchymal stem cells (hMSCs), the precursors of 
osteoblasts, may be compromised in elderly individuals, in relation with the epigenetic changes 
associated with aging. However, the role of hMSCs in the pathogenesis of osteoporosis is still unclear. 
 Therefore we aimed to characterize the genome-wide methylation and gene expression signatures and 
the differentiation capacity of hMSCs from patients with hip fractures. We obtained hMSCs from the 
femoral heads of women undergoing hip replacement due to hip fractures and controls with hip 
osteoarthritis. DNA methylation was explored with the Infinium 450K bead array. Transcriptome 
analysis was done by RNA sequencing. The genomic analyses revealed that most differentially 
methylated loci were situated in genomic regions with enhancer activity, distant from gene bodies and 
promoters. These regions were associated with differentially-expressed genes enriched in pathways 
related to hMSC growth and osteoblast differentiation. hMSCs from patients with fractures showed 
enhanced proliferation and up-regulation of the osteogenic drivers RUNX2/OSX. Also, they showed 
some signs of accelerated methylation aging. When cultured in osteogenic medium, hMSCs from 
patients with fractures showed an impaired differentiation capacity, with reduced alkaline phosphatase 
and poor accumulation of a mineralized matrix.  Our results point to two areas of potential interest for 
discovering new therapeutic targets for low bone mass disorders and bone regeneration: the 
mechanisms stimulating MSCs proliferation after fracture and those impairing their terminal 
differentiation. 
 
RUNNING TITLE: Transcriptome and Methylome Analysis of MSCs in Fractures and 
Osteoarthritis. 
KEYWORDS: Osteoporosis, Osteoarthritis, Epigenetics, Stem cells, Transcription factors. 
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INTRODUCTION 
Osteoporotic hip fractures have a particularly negative impact on the patients’ quality of life and life 
expectancy. The pathogenetic mechanisms of osteoporosis are not completely understood, but they 
imply an imbalance in bone remodelling, with a predominance of bone resorption over bone 
formation. Osteoblasts are the cells responsible for bone formation. Human mesenchymal stem cells 
(hMSCs) are pluripotent cells capable of differentiating into osteoblasts, chondrocytes, adipocytes and 
myoblasts. Therefore, hMSCs are the subject of considerable interest from a double perspective. On 
the one hand, hMSC malfunction may be involved in the pathogenesis of osteoporosis 1,2. Thus, 
elucidating the mechanisms involved in hMSCs proliferation and differentiation could point to new 
drug targets to improve osteoblast function in osteoporotic patients. On the other hand, the infusion of 
hMSCs could theoretically improve bone formation systemically or locally. A few studies tried to 
characterize hMSCs from patients with osteoporosis, but the results are controversial 3–5. Therefore, 
much more basic research is needed to characterize hMSCs in osteoporosis prior to use them for the 
treatment of skeletal disorders.  
Epigenetic mechanisms play an important role in skeletal biology. In particular, DNA methylation has 
been shown to modulate the differentiation of cells towards the osteoblastic lineage 6,7. Thus, it is 
tempting to speculate that changes in DNA methylation influence the differentiation capability of 
hMSCs in osteoporosis. However there are only scarce data about the methylation signature of skeletal 
hMSCs. Therefore, we aimed to perform a genome-wide methylome analysis of hMSCs from patients 
with hip fractures and explore the functional consequences at the transcriptome level and the ability to 
proliferate and differentiate in vitro. 
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RESULTS 
Isolation and characterization of hMSCs 
We had similar success rate in establishing an hMSC culture with samples obtained from patients with 
fractures (27 out of 41, 66%) or with OA (22 out of 32, 69%). The hMSC phenotype was confirmed 
by flow cytometry using a combination of markers (CD45-, CD34-, CD90+, CD73+, CD105+) that 
define the phenotype of bone marrow hMSCs 2 (Supplemental Fig. S1).   
DNA methylation profiling 
When the interrogated CpGs were grouped according to their genomic position, gene bodies were 
more methylated than CG islands or gene promoters (Supplemental Figs. S2 and S3). The average 
methylation level was similar in both study groups. Nevertheless, among the 477708 sites explored, 
we found 9038 differentially methylated CpG sites. Of them, 4417 were more methylated and 4621 
were less methylated in samples obtained from osteoporotic patients with hip fracture (FRX). Among 
the differentially methylated CpG sites, 1586 sites were located in CpG islands, 1105 in shores, 353 in 
shelves and 5994 sites in open sea.  
The analysis at the region level revealed 217 out of 30877 gene promoters with differential 
methylation, which correspond to 71 protein coding genes, of a total of 21191 different genes, 
including 111 more methylated and 106 less methylated in FRX. Regarding gene bodies, 62 were 
found more methylated and 67 less methylated in FRX. Among CG islands, 16 were more methylated 
and 24 less methylated in FRX (Table 1 and Supplemental Fig. S4). 
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Differential methylated sites were enriched in enhancers regions (which included 2425 of the 9038 
differentially methylated CpGs). The distances to the transcription start sites (TSSs) are shown in 
Supplemental Figure S5. The region level analysis revealed 1684 differential methylated gene 
enhancer regions; 870 regions (associated with 722 protein-coding genes) were hypermethylated and 
814 (678 genes) were hypomethylated in FRX in comparison with OA (Supplemental Table S1 and 
Figure 1A). Most FRX and OA samples tended to be grouped in common clusters, but there was some 
degree of overlapping, as shown in Fig. 1B. Genes with differentially-methylated enhancers were 
overrepresented among pathways related to stem cell development and bone-related pathways, like the 
Wnt receptor signaling pathway (p=4.5x10-8 binomial test), regulation of osteoblast differentiation 
(p=9.1x10-5), regulation of hMSCs proliferation (p=7.6x10-6) and bone mineralization (p=7.6x10-4) 
pathways (Supplemental Fig. S6). 
Gene expression analysis  
Overall, 11390 genes were expressed in both FRX and OA samples, whereas 496 genes were 
expressed only in FRX and 1695 in OA. As expected, the gene expression signature was typical of 
hMSCs (Supplemental Table S2). Overall, 99 protein-coding genes were up-regulated in FRX 
(FDR<0.10 and fold-change>2), whereas 239 were down-regulated (Supplemental Fig. S7 and 
Supplemental Table S3). The top 50 up- or down-regulated genes are shown in Tables 2 and 3. 
Among genes with differential expression, those up-regulated in FRX were enriched in pathways 
related to hMSCs differentiation and bone formation, whereas those down-regulated in FRX were 
enriched in pathways related to the immune response, among others (Supplemental Table S4).  
Correlation between differential DNA methylation and differential gene expression 
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Genes with differentially methylated enhancers were overrepresented among those showing 
differential expression (19.8% versus 9.2% in those without differential expression; p=1.2x10-10). The 
direction of the association was variable, but there was a trend for an inverse correlation between 
enhancer methylation and expression (Odds Ratio [OR] 0.3; 95% confidence interval 0.12-0.99; 
p=0.05). This is schematically depicted in Fig. 2A, showing that 18 genes up-regulated in FRX had 
differentially methylated enhancers, 8 hypermethylated and 10 hypomethylated. On the other hand, 55 
genes down-regulated in FRX had differentially methylated enhancers; 39 hypermethylated and 16 
hypomethylated. Examples of the individual values of expression and methylation of some genes are 
shown in Supplemental Fig. S8. The comparative Gene Ontology Enrichment analysis revealed that 
genes with hypomethylated enhancers and up-regulated expression in fractures were overrepresented 
in pathways related to hMSCs proliferation, osteoblast differentiation and bone mineralization, as well 
as some neuron-related pathways (Figure 2B and Supplemental Figure S9).   
Validation of expression and methylation differences across groups 
We confirmed, by qPCR, the expression pattern of 10 genes among those that showed differential 
expression in the RNAseq analysis (SPARC, LOXL2, FOXP2, LAMC1, SLC5A3, OPG, ID2, LASP1, 
IGFBP4 and UNC5B), including 8 samples previously analysed by RNAseq and 19 new samples. 
There were strong correlations in the individual results obtained with both techniques (Supplemental 
Figs S10 and S11). Similarly, to validate the results obtained with the 450k array, we analysed by 
pyrosequencing four genes showing differential methylation according to array data analysis 
(Supplemental Figure S12). 
DNA methylation age 
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We studied the DNA methylation aging in our samples by using a software based on Illumina DNA 
Infinium 450K data that analyses a set of genes showing age-related changes in methylation. There 
was a significant correlation between the epigenetic age and the chronological age (r=0.64, p=1.357e-
05). The slopes of the regression lines were similar in both patient groups (Figure 3, left panel), but the 
lines were vertically displaced. Therefore, when the regression was computed with both groups 
combined, the deviations of the epigenetic age from the chronological age were higher in the FRX 
group than in the OA group, thus suggesting accelerated epigenetic aging in the former (Fig. 3, right 
panel).  
Proliferative capability of hMSCs 
Interestingly, the proportion of actively-dividing, Ki-67 positive cells was significantly higher among 
hMSCs grown from patients with FRX (Figure 4A). These results agreed with those obtained from a 
MTT assay, which confirmed a higher proliferation rate in hMSCs cultures established from patients 
with fractures (Figure 4B).  
Transcriptional signature and bone differentiation capacity of hMSCs 
Analysis of the gene expression levels of a set of osteogenic and adipogenic markers showed 
significant differences in the expression levels of key osteogenic genes (Figure 4C), such as OSX, 
ALPL, SPP1 and BGLAP, between patients with osteoporotic fractures and OA. These data agreed and 
validated the previously shown results from the RNAseq analysis. Interestingly, OSX, a key 
transcription factor expressed in the first stages of osteoblast development was significantly up-
regulated in hMSCs from patients with FRX whereas collagen expression was similar in both groups. 
Markers, such as ALPL and SPP1, normally expressed later on during the osteogenic differentiation 
process, were down-regulated in hMSCs isolated from patients with osteoporotic fractures. On the 
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other hand, adipogenic markers, such as PPARG and LPL, were expressed less abundantly in patients 
with fractures than in those with OA (Fig. 4C). 
In line with their hMSC phenotype, the cells were able to differentiate normally into adipocytes and 
osteoblasts (Fig. 5A). However, there were marked differences between groups and the capacity to 
form a mineralized matrix was markedly diminished in hMSCs from patients with FRX (p=0.00015; 
Fig. 5B). The alkaline phosphatase activity in hMSC cultures from FRX was also much lower than in 
cultures of OA origin (Fig. 5C), and there was a correlation between alkaline phosphatase activity and 
matrix mineralization (Spearman’s rho 0.84, p<0.001). On the other hand, there was a tendency for 
enhanced OSX and RUNX2 expression in FRX cells (Fig. 5D).    
DISCUSSION 
We have previously shown that modifications in DNA methylation play a central role in the 
differentiation of cells along the osteoblastic lineage and that genes related to skeletal development are 
differentially methylated in bone samples of patients with osteoporotic fractures 8. In the present study, 
we explored the epigenome of hMSCs in patients with fractures. To our knowledge, this is the first 
study combining epigenome-wide and transcriptome-wide analyses of hMSCs in osteoporosis. We 
established that the methylation signatures of hMSCs from patients with fractures and OA show 
significant differences at the enhancer regions of a number of genes related to cell proliferation and 
differentiation.  
Our study has some limitations. The method used does not allow distinguishing methylated and 
hydoxymethylated cytosines. Due to practical reasons, we isolated hMSCs from the bone marrow of 
OA patients rather than normal bone marrow as comparison controls. Nevertheless, it has been 
suggested that MSCs from OA patients have similar proliferation and osteogenic differentiation 
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capacity to MSCs from healthy donors 9. Also, we removed the subchondral region, thus trying to 
avoid the potential influence of the changes taking place in the subchondral bone 10. Aging is 
associated with methylation differences in some genes 11 and patients with fractures were somewhat 
older than those with OA. Nevertheless, we adjusted the results including age as a covariate to avoid 
any age-related bias. Also, due to the low percentage of hMSCs in bone marrow (less than 1/10,000 to 
1/100,000) hMSCs needed to be expanded in vitro prior to the analysis. However, to avoid changes in 
the epigenome signature that could bias the results, in vitro expansion was kept to a minimum and 
only cells at first passage were used for the analyses. 
The classical view of DNA methylation tended to associate increased methylation with decreased gene 
expression and vice versa. However, our results confirm that the relationship between methylation and 
expression is indeed variable. Although increased methylation was associated with a decreased 
expression of many genes, the opposite was also true. In fact, that seems to be the case in other cell 
types 12,13. Additionally, as previously reported in other conditions, including the osteoarthritic 
cartilage 14,15, most differentially methylated regions do not appear to be at the gene bodies or at 
promoter regions, but at genomic regions with enhancer activity distant from the promoter. Thus, 
changes in methylation at regulatory regions may influence the expression of genes situated several 
hundred kilobases away. Also, as shown in our genomic region analysis, most regions showing 
differential methylation between groups appear to be outside CpG islands. 
Rather unexpectedly, hMSCs from patients with hip fractures tended to display up-regulation of genes 
linked to cell proliferation pathways, in parallel with a decreased methylation of their enhancer 
regions. Those genes were over-represented in important pathways, such as those regulating cell 
proliferation, osteoblast differentiation or vasculogenesis. This translated into an increased 
proliferation of these cells, in comparison with cells from patients with OA, in line with the concept 
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that fractures activate and mobilize hMSCs and are consistent with previous reports showing a 
mobilization of MSCs into the circulation in response to fracture 16. The mechanisms involved remain 
to be elucidated, but may include the release of activating cytokines and activation of the Wnt 
pathway, as suggested by our enrichment analysis. Wnt ligands promote the proliferation of 
osteoblasts precursors 17,18. In line with this, Baht et al. recently reported that hematopoietic cells of 
young mice are able to stimulate the osteoblastic responses in aged animals by a mechanism that 
involves β-catenin, a critical signaling mediator of the canonical Wnt pathway 19. Neural-mediated 
mechanisms may also be included, as suggested by the enhanced bone formation shown by patients 
with head trauma 20 and the differential methylation and expression of some genes in nervous tissue-
related pathways also found in the present study.   
MSCs from fracture patients showed an up-regulation of the genes driving osteogenic differentiation, 
such as RUNX2 and OSX. The expression of some genes such as BGLAP and IBSP, usually considered 
as characteristic of the osteoblastic phenotype and targets of RUNX2, was also increased in hMSCs 
from fracture patients in basal conditions. However, those hMSCs showed a reduced ability to from a 
mineralized matrix when cultured in osteogenic medium. This could be related to a decreased activity 
of alkaline phosphatase, which plays a critical role in mineralization, or to the persistent up-regulation 
of RUNX2. RUNX2 is a master driver of osteoblast precursor differentiation 21. Specific epigenetic 
marks contribute to the regulation of RUNX2 expression 22. RUNX2 controls bone development and 
osteoblast differentiation by regulating the expression of a significant number of bone-related target 
genes, including collagen, osteocalcin, osteopontin, bone sialoprotein and osteoprotegerin. Thus, it 
plays a critical role in the early stages of differentiation of hMSCs into pre-osteoblasts. However, after 
this initial step, RUNX2 expression must be turned down to allow terminal differentiation of 
osteoblasts 23.  
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Recent experiments in rodent models of osteoporosis have shown that the MSC transplantation may 
have a positive effect on bone mass locally and even systemically 24,25. Additionally, molecules 
helping to target deliver MSCs into bone are being developed 26. This raises the possibility of using 
MSCs for bone regeneration, fracture consolidation or treating widespread bone loss. Since allogenic 
transplants of MSCs pose difficulties related to histocompatibility, in clinical practice autologous 
transplants would be preferable. In this line, our results are encouraging because they show that, 
despite some accelerated epigenetic aging, hMSCs from patients with fragility fractures are activated 
and maintain a good proliferation capacity, rendering them potentially useful for autologous 
transplants. Indeed, these cells were able to express genes encoding several proteins present in bone 
matrix in quantities similar to those expressed by cells from OA patients, which have been reported to 
behave similarly to MSCs from healthy subjects 9. However, their ability for terminal differentiation 
and the formation of a mineralized matrix appear to be compromised, at least in vitro. Hence, it would 
be highly desirable to reach a better understanding of the mechanisms impairing that ability in order to 
circumvent them with the final objective of optimizing bone matrix formation in vivo. 
In summary, the epigenome-wide signature of hMSCs from fracture patients shows differentially 
methylated regions in comparison with hMSCs derived from OA patients. Most differences are in 
genomic regions with enhancer activity, distant from gene bodies and apart from CpG islands. They 
are associated with up-regulation of a number of genes involved in MSC proliferation and 
differentiation, including an up-regulation of genes such as RUNX2/OSX driving the differentiation 
towards an osteoblastic phenotype. However, their ability to form a mineralized matrix appears to be 
impaired. These results point to two areas of potential interest for discovering new therapeutic targets 
for low bone mass disorders and bone regeneration: the mechanisms stimulating MSCs after fracture 
and the mechanisms impairing the terminal differentiation of MSCs. Additionally, these results 
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emphasize the concept that modifications of DNA methylation may have a cis-influence on rather 
distant genes. 
 
MATERIALS AND METHODS 
Human Mesenchymal Stem Cells (hMSCs) isolation and culture 
Bone marrow hMSCs were obtained from the femoral heads of patients undergoing replacement 
surgery due to osteoporotic hip fractures (FRX; n=25, age 62 to 88 yrs) or hip osteoarthritis (OA; 
n=17, age: 72 to 92 yrs). They included female patients with osteoporotic hip fractures or hip 
osteoarthritis. Patients with high-impact fractures, secondary osteoporosis or secondary OA were 
excluded. All patients gave informed written consent. The study protocol was approved by the 
institutional review board (Comité de Etica en Investigación Clínica de Cantabria). Cylinders of 
trabecular bone were extracted with a trephine, after removing the subchondral and subfracture edges, 
they were washed with 50 mL of phosphate-buffered saline (PBS).  Cells were subjected to a density 
Ficoll gradient. Then, 2 x106 per cm2 were cultured on polystyrene culture flasks in MesencultTM MSC 
Basal media completed with 10% of Mesenchymal Stem Cell Stimulatory supplements (Stem Cell 
Technologies®, Vancouver, Canada). Representative samples were characterized by staining for 
surface markers in a FACSCanto II flow cytometer (Becton Dickinson, New Jersey, USA) after 
labelling with antibodies against CD45, CD34, CD73, CD90 and CD105.   
Genome-wide methylation analysis  
Since only MSCs at first passages were used for the experiments, there had a limited number of cells 
to perform all experiments with some of the hMSC lines. Thus, only 22 FRX and 17 OA samples of all 
the samples initially harvested were used for the analyses of DNA methylation (patients age: 62 to 95 
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yrs). DNA was extracted with Phenol:Chloroform:Isoamyl Alcohol and bisulfite-converted prior to 
genome-wide analysis of methylation with the Infinium Human Methylation450 BeadChip array 
(Illumina®, San Diego, CA, USA) in the Spanish “Centro Nacional de Genotipado” (CEGEN-ISCIII). 
Raw data files were pre-processed using R/Bioconductor package RnBeads, 27 and methylation was 
described as β value, which ranges between 0 (no methylation) to 1 (full methylation).Analyses were 
conducted at the single CpG site level and at various region levels, including age as a covariate. 
Regions with FDR<0.05 and an absolute difference in methylation higher than 10% (Δβ>0.10) were 
considered as differentially methylated. Annotation data for the genomic enhancers' study were 
retrieved from the H1 embryonic stem cell line from the UCSC Table Browser. 
The methylation level of selected CpGs was replicated by pyrosequencing (PyromarkQ24 Advanced 
System®). Primers used for PCR amplification and sequencing were designed with the PyroMark 
assay designer (Supplemental Table S5). The statistical significance of the differences between FRX 
and OA patients was tested by Mann-Whitney tests, with a significance threshold of 0.05. 
Transcriptome analysis 
RNA was isolated from hMSCs (n=10 FRX and n=10 OA) using Trizol® (Thermofisher Scientific, 
Waltham, MA, USA). After quality check and quantitation, the samples were prepared using the 
NEBNext Ultra Directional RNA Library Protocol.  Samples were sequenced on an Illumina Hi-seq 
2000 sequencer (NTX-Dx, Gent, Belgium). Sample reads were mapped to the human reference 
genome build GRCh37. Expression analysis was done with cufflinks v2.1.1 on Gencode Annotation 
v15. FPKM values were calculated for each annotated gene and transcript. RNAseq analysis was 
carried out at the transcript level with Altanalyze software 28 and at the gene level with the 
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Bioconductor package EdgeR 29. Genes with FDR<0.10 and fold-changes >2 were regarded as 
differentially expressed.  
Enrichment analyses of the genes with differentially-methylated enhancers were obtained from the 
output of GREAT software 30. The overrepresentation of genes with differential expression in different 
cell pathways (Wikipathways) was obtained from the output of WEBGESTALT software 31, which 
incorporates information from different public resources. The Gene Ontology enrichment analyses 
from the common terms between differentially-methylated enhancers and differential expression were 
done with ArrayTrack software 32. 
RNAseq data and expression of selected genes were confirmed by using real-time quantitative PCR 
(qPCR), after reverse-transcription of RNA into cDNA, using the housekeeping genes GAPDH and 
RPL13A for normalization. Assay details are given in Supplemental Table S5. 
DNA methylation age 
The epigenetic age was calculated from the methylation level of a set of 353 CpGs which has been 
shown to change with aging in a wide variety of tissues 33. The relationship of the epigenetic age and 
the chronological age was explored by linear regression analysis.   
Proliferation Analysis 
The proliferation status of hMSCs was assessed by immunocytochemistry using an anti-Ki-67 
antibody, a nuclear protein associated with cell proliferation. The results were confirmed by a cell 
proliferation colorimetric assay based on the reduction of the tetrazolium dye MTT.    
Osteogenic and Adipogenic Differentiation 
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hMSCs were cultured in osteogenic induction medium (low glucose Dulbecco Modified Eagle 
Medium (DMEM) with 10% FBS, 50 µM ascorbic acid, 10 mM β-glycerophosphate, 100 nM 
dexamethasone) or adipogenic induction medium (DMEM, supplemented with 1.0 M dexamethasone, 
0.2 mM indomethacin, 0.5 mM 3-isobutyl-1-methylxanthine, 10% FBS). hMSCs were plated in a 24 
wells plate and incubated for up to 3 weeks, prior to staining or RNA extraction. The formation of 
mineralized matrix was assessed by Alizarin Red staining. The staining was evaluated 
semiquantitatively by two independent observers who were blind of the culture origin. Other wells 
were used to determine alkaline phosphatase activity in cell lysates by a colorimetric method based on 
the ability of ALPL to hydrolyze p-nitrophenylphosphate, 34. Oil Red was used to visualize the 
presence of lipid droplets.  
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FIGURE LEGENDS 
Fig 1. Methylation analysis of hMSCs. (A) Volcano plots of DNA methylation differences in enhancer 
regions of hMSCs obtained from fractures and OA. Coloured in green, plots with a FDR<0.05 and 
absolute beta differences larger than 0.1 (B) Heat-map showing beta values of enhancer regions. In red 
more methylated and in green less methylated. Samples are named with a lab identifier code (JAR). 
 
Fig 2. Relationship between methylation and gene expression signatures. (A) Venn diagram 
summarizing the association between differential DNA methylation and differential gene expression 
(comparisons of hMSCs from fractures over hMSCs from controls). (B) Pathways enrichment analysis 
of genes with hypomethylated enhancers that were up-regulated in fractures.   
Fig 3. Epigenetic aging of hMSCs. Left: Comparison of epigenetic and chronological age. Regression 
lines for each patient group are shown. Right: Deviation from the overall regression line with the two 
groups combined (mean and SE residuals in each patient group). 
 
Fig 4. Proliferation capacity and expression of selected genes by hMSCs from patients with fractures 
(FRX) and osteoarthritis (OA). (A) Proliferation assessed by Ki67 staining. (B) Proliferation by a MTT 
assay. (C) Expression of osteogenic markers by hMSCs from FRX and OA. (D) Expression of 
adipogenic markers by hMSCs. 
 
Fig 5. Differentiation capacity of hMSCs. (A) Osteogenic and adipogenic differentiation of hMSCs, as 
revealed by Alizarin red staining and Oil red staining, respectively. (B) Osteogenic differentiation of 
hMSCs from patients with fractures (FRX) and with osteoarthritis (OA), semiquantitative analysis. (C) 
Alkaline phosphatase activity in hMSC maintained in osteogenic medium. (D) Expression of the 
22 
 
osteoblastic differentiation drivers OSX and RUNX2 in hMSCs from patients with FRX and OA 
maintained in osteogenic medium.  
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Table 1. Distribution of differentially methylated CpGs between MSCs from 
fracture patients (FRX) and patients with osteoarthritis in various genomic regions. 
Genomic 
regions 
Differentially 
methylated 
CpG sites 
Analyzed 
regions 
Differential 
methylated 
regions 
Regions more 
methylated in 
FRX 
Regions less 
methylated in 
FRX 
Promoters 402 30877 217 111 106 
Gene bodies 1355 30725 129 62 67 
CpG islands 124 26649 40 16 24 
Enhancers 2425 41280 1684 870 814 
 
Table 2. Top 50 up-regulated expressed genes in fractures. Gene symbol 
and complete gene name are shown. Each gene with their corresponding fold 
change value and corrected p-value (FDR). 
Gene 
symbol 
Gene name Fold-
Change 
FDR 
LGR6 Leucine-Rich Repeat-Containing G-Protein Coupled Receptor 6 11.6 0.0083 
BGLAP Bone Gamma-Carboxyglutamate Protein 10.3 0.0226 
GNGT1 G Protein Subunit Gamma Transducin 1 9.1 0.0574 
KLRC2 Killer Cell Lectin Like Receptor C2 8.9 0.0083 
GLB1L3 Galactosidase Beta 1 Like 3 8.1 0.0046 
RANBP3L RAN Binding Protein 3 Like 7.4 0.0604 
PKD1P6 Polycystin 1, Transient Receptor Potential Channel Interacting Pseudogene 6  7.3 0.0163 
IBSP Integrin Binding Sialoprotein 6.1 0.0028 
RTEL1 Regulator Of Telomere Elongation Helicase 1 5.8 0.0399 
INSC Inscuteable Spindle Orientation Adaptor Protein 5.7 0.0284 
SORCS2 Sortilin Related VPS10 Domain Containing Receptor 2 5.7 0.0383 
ACAD8 Acyl-CoA Dehydrogenase Family Member 8 5.0 0.0143 
SLC12A7 Solute Carrier Family 12 Member 7  5.0 0.0386 
OSBP2 Oxysterol Binding Protein 2  5.0 0.0824 
SCN9A Sodium Voltage-Gated Channel Alpha Subunit 9 4.9 0.0399 
BMP2 Bone morphogenetic protein 2 4.8 0.051 
LSP1P2 Lymphocyte-Specific Protein 1 Pseudogene 2 4.8 0.0456 
ETV1 ETS Variant 1 4.8 0.0979 
DNM1 Dynamin 1 4.7 0.0642 
TRIM59 Tripartite Motif Containing 59 4.6 0.0815 
COL8A2 Collagen type VIII alpha 2 chain 4.1 0.0284 
TNNC1 Troponin C1, Slow Skeletal And Cardiac Type 4.1 0.0703 
STMN3 Stathmin 3 4.1 0.0274 
GRIA1 Glutamate Ionotropic Receptor AMPA Type Subunit 1 4.1 0.0806 
LRRC17 Leucine Rich Repeat Containing 17 4.0 0.0854 
CACNA1G Calcium voltage-gated channel subunit alpha1 G 3.9 0.0972 
TRIM7 Tripartite Motif Containing 7 3.9 0.0384 
ARFRP1 ADP Ribosylation Factor Related Protein 1 3.9 0.095 
BTBD11 BTB Domain Containing 11 3.9 0.0924 
AMOT Angiomotin 3.8 0.0129 
GALNTL1 Polypeptide N-Acetylgalactosaminyltransferase 16 3.7 0.0686 
TNFRSF11B Osteoprotegerin 3.7 0.0284 
NCAM1 Neural Cell Adhesion Molecule 1 3.7 0.0151 
RNF112 Ring Finger Protein 112 3.7 0.0797 
GALNT3 Polypeptide N-Acetylgalactosaminyltransferase 3 3.6 0.0289 
STXBP6 Syntaxin Binding Protein 6 3.6 0.058 
ABCA3 ATP Binding Cassette Subfamily A Member 3 3.6 0.0284 
MEOX2 Mesenchyme Homeobox 2 3.6 0.0797 
TCEAL7 Transcription Elongation Factor A Like 7 3.5 0.0972 
EMBP1 Embigin Pseudogene 1 3.5 0.0686 
LOXL4 Lysyl Oxidase Like 4 3.5 0.0979 
PCDH10 Protocadherin 10 3.5 0.0284 
FBXL13 F-Box And Leucine Rich Repeat Protein 13 3.4 0.0183 
SYT12 Synaptotagmin 12 3.3 0.0686 
LRRC15 Leucine Rich Repeat Containing 15 3.3 0.0884 
DNAJC22 DnaJ Heat Shock Protein Family (Hsp40) Member C22 3.1 0.0586 
P2RX6 Purinergic Receptor P2X 6 3.1 0.051 
CXorf57 Chromosome X Open Reading Frame 57 3.1 0.0284 
ENPP1 Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 2.9 0.028 
SERPINF1 Serpin Family F Member 1 2.9 0.0609 
 
Table 3. Top 50 down-regulated expressed genes in fractures. Gene 
symbol and complete gene name are shown. Each gene with their corresponding 
fold change value and corrected p-value (FDR). 
Gene 
Symbol 
Gene name Fold-
Change 
FDR 
IGHG4 Immunoglobulin Heavy Constant Gamma 4 (G4m Marker) 125.4 0.0274 
IGHD Immunoglobulin Heavy Constant Delta 56.9 0.0279 
IGHJ4 Immunoglobulin Heavy Joining 4 48.5 0.0624 
IGKV2-28 Immunoglobulin Kappa Variable 2-28 43.4 0.0596 
IGHGP Immunoglobulin Heavy Constant Gamma P 43.1 0.0284 
IGKV3-20 Immunoglobulin Kappa Variable 3-20 32.9 0.0183 
IGKV4-1 Immunoglobulin Kappa Variable 4-1 26.5 0.0806 
IGHG3 Immunoglobulin Heavy Constant Gamma 3 25.1 0.0128 
CHL1 Cell Adhesion Molecule L1 Like 22.6 0.0224 
SYNPO2 Synaptopodin 2 21.7 0.0018 
IGKV1-5 Immunoglobulin Kappa Variable 1-5 21.7 0.0518 
IGKV1-6 Immunoglobulin Kappa Variable 1-6 21.7 0.0624 
IGLC2 Immunoglobulin Lambda Constant 2 21.6 0.0992 
LYZ Lysozyme 18.1 0.0016 
IGHA1 Immunoglobulin Heavy Constant Alpha 1 17.0 0.0199 
CHRDL1 Chordin Like 1 16.0 0.0372 
CPA3 Carboxypeptidase A3 15.6 0.0651 
SLC24A3 Solute Carrier Family 24 Member 3 15.2 0.0182 
IGLC3 Immunoglobulin Lambda Constant 3 14.8 0.0967 
IGJ Joining Chain Of Multimeric IgA And IgM 14.2 0.0227 
IGHG1 Immunoglobulin Heavy Constant Gamma 1 13.8 0.0339 
DERL3 Derlin 3 13.0 0.0486 
TMEM176A Transmembrane Protein 176A 12.8 0.0935 
IGLJ3 Immunoglobulin Lambda Joining 3 12.6 0.0856 
ACTG2 Actin, Gamma 2, Smooth Muscle, Enteric 12.1 0.0711 
IL32 Interleukin 32 11.9 0.0474 
CD27-AS1 CD27 Antisense RNA 1 11.6 0.0076 
CRISPLD2 Cysteine Rich Secretory Protein LCCL Domain Containing 2 11.3 0.0286 
ID4 Inhibitor Of DNA Binding 4, HLH Protein 11.3 0.0028 
LPAL2 Lipoprotein(A) Like 2 11.1 0.0058 
IGHG2 Immunoglobulin Heavy Constant Gamma 2 10.7 0.038 
CP Ceruloplasmin 10.6 0.0301 
NDE1 NudE Neurodevelopment Protein 1 10.4 0.0577 
TMTC3 Transmembrane And Tetratricopeptide Repeat Containing 3 10.4 0.0576 
SLC5A3 Solute Carrier Family 5 Member 3 9.7 0.0687 
STX12 Syntaxin 12 9.6 0.085 
HIST1H2AC Histone Cluster 1 H2A Family Member C 9.6 0.0989 
ATXN1L Ataxin 1 Like 9.6 0.0429 
MUC15 Mucin 15, Cell Surface Associated 9.5 0.0204 
CHL1-AS2 CHL1 Antisense RNA 2 9.3 0.0207 
IGKV3D-20 Immunoglobulin Kappa Variable 3D-20 9.3 0.0824 
ARHGAP20 Rho GTPase Activating Protein 20 9.2 0.0337 
ADCY2 Adenylate Cyclase 2 9.1 0.0348 
SLC22A3 Solute Carrier Family 22 Member 3 8.6 0.0274 
PMP22 Peripheral Myelin Protein 22 8.3 0.0358 
CDKN1C Cyclin Dependent Kinase Inhibitor 1C 8.3 0.037 
CD38 CD38 Molecule 8.2 0.0972 
ENTPD1 Ectonucleoside Triphosphate Diphosphohydrolase 1 8.1 0.0158 
TFRC Transferrin Receptor 7.9 0.0483 
KREMEN1 Kringle Containing Transmembrane Protein 1 7.8 0.0769 
 
